

Supplementary Table S4—Number of dogs in Table S1 with urinalysis abnormalities following 4 weeks of dosing.*

Parameter	RR	Placebo	1 mg/kg	2 mg/kg	4 mg/kg	12 mg/kg
		dogs (n)	dogs (n)	dogs (n)	dogs (n)	dogs (n)
Specific gravity	1.015-1.050	1	1	2	1	1
pH	5.5-7.0	1	1	-	1	-
Protein	Neg	-	-	2	1	-
Blood	Neg	-	1	-	1	-
WBC	0-3 HPF	-	1	-	-	-
RBC	0-3 HPF	-	1	-	1	-
Struvite crystals	HPF	-	-	2	-	2
Calcium oxalate dihydrate crystals	HPF	2	1	1	-	1
Calcium oxalate monohydrate crystals	HPF	1	1	-	-	2
Amorphous phosphate crystals	HPF	1	-	1	1	-
Brushite crystals	HPF	1	-	-	-	-
Epithelial cells	HPF	-	-	-	-	-
Bacteria	None	-	1	1	1	1
Bilirubin	Neg to 1+	-	-	1	-	-
Glucose	Neg	-	-	-	-	-
Ketone	Neg	-	-	-	-	-
Casts	HPF	-	-	-	-	-
Fat droplets	None	-	-	-	-	-

HPF, high power field; n, number; Neg, negative; RR, reference range

*Urine samples were collected at baseline (one day prior to treatment) and following two and four weeks of dosing. The table summarizes abnormalities detected at the end of Week 4 that were not also observed at baseline; as such, abnormalities detected at Week 4 that were also present at baseline are not reported.